Structure Therapeutics (NASDAQ:GPCR) Raised to “Strong-Buy” at The Goldman Sachs Group

Structure Therapeutics (NASDAQ:GPCR) was upgraded by equities researchers at The Goldman Sachs Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

GPCR has been the subject of several other reports. JPMorgan Chase & Co. upped their target price on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 11th. Citizens Jmp raised their target price on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Price Performance

Shares of GPCR opened at $91.87 on Tuesday. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The company’s fifty day moving average price is $59.82 and its 200-day moving average price is $36.02. The firm has a market capitalization of $5.57 billion, a PE ratio of -75.30 and a beta of -2.05.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, research analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. State of Wyoming acquired a new position in Structure Therapeutics in the second quarter valued at $28,000. EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the period. PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after buying an additional 994 shares during the period. Finally, ANTIPODES PARTNERS Ltd raised its holdings in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after buying an additional 1,146 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.